Abstract
Studies designed to compare valproic acid (VPA) with its α-fluorinated derivative (F-VPA) for their abilities to form acyl-CoA thioester derivatives in vivo are described. Recent studies have shown that α-fluorination of a hepatotoxic metabolite of VPA (Δ4-VPA) resulted in a nonhepatotoxic derivative. We hypothesize that the decrease in hepatotoxicity may be related to a lack of formation of the intermediary acyl-CoA thioester. To determine the effect of α-fluoro substitution on acyl-CoA formation, we synthesized F-VPA and compared it with VPA for its ability to form the acyl-CoA thioester derivative in vivo in rat liver. Thus, after dosing rats with VPA or F-VPA, animals were sacrificed (0.05-, 0.5-, 1-, 2-, and 5-h postadministration) for the analysis of liver tissue. High-performance liquid chromatography (HPLC) and electrospray ionization/tandem mass spectrometry analysis of liver extracts from VPA-dosed rats showed the presence of VPA-CoA that was maximal after 0.5 h (185 nmol/g of liver) and was still measurable 5-h postadministration (90 nmol/g of liver). In agreement with our hypothesis, F-VPA did not form the corresponding acyl-CoA derivative as determined by the absence of F-VPA-CoA upon HPLC analysis of liver extracts from F-VPA-dosed rats. Further examination of liver tissue for the presence of free acids revealed that the differences in acyl-CoA formation cannot be explained by differences in VPA and F-VPA free acid concentrations. From these observations and related studies showing the lack of toxicity due to α-fluoro substitution, we propose that metabolism of VPA by acyl-CoA formation may mediate the hepatotoxicity of the drug.
Footnotes
-
↵1 Present address: Pharmacia, Global Metabolism and Investigative Sciences, 301 Henrietta St., Kalamazoo, MI 49007.
-
This work was supported in part by National Institutes of Health Grant GM36633. Preliminary accounts of this work were presented at the Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA, April 2000. The University of California at San Francisco Mass Spectometry Facility is supported by the Biomedical Research Technology Program of the National Center for Research Resources, National Institutes of Health Grant RR01614, and National Science Foundation Grant DIR 8700766.
- Abbreviations used are::
- VPA
- valproic acid
- VPA-CoA
- valproyl-S-acyl-CoA
- F-VPA
- α-fluorovalproic acid
- F-VPA-CoA
- α-fluorovalproyl-S-acyl-CoA
- Δ4-VPA
- unsaturated metabolite of VPA
- F-Δ4-VPA
- α-fluorinated analog of Δ4-VPA
- Δ2,4-VPA
- hepatotoxic metabolite of Δ4-VPA
- GSH
- glutathione
- BSTFA
- bis(trimethylsilyl)trifluoroacetamide
- CID
- collisionally induced dissociation
- THF
- tetrahydrofuran
- ESI/MS/MS
- electrospray ionization/tandem mass spectrometry
- GC/MS
- gas chromatography/mass spectrometry
- HPLC
- high-performance liquid chromatography
- Received January 24, 2001.
- Accepted May 19, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|